Summary: Chronic Pain and the Opioid Shadow

Thirty-six percent of Americans over 65 report chronic pain, meaning pain on most days for three months or more. More than one in three say it limits their daily activities. The healthcare system has figured out how to make the problem worse. Twice.

First came overprescription. In the late 1990s, pharmaceutical companies marketed opioids as safe for chronic non-cancer pain. Prescriptions nearly tripled between 1999 and 2012. Older adults received a disproportionate share. Falls increased. Cognitive impairment worsened. People died. Then came the overcorrection. The CDC’s 2016 guidelines were intended as clinical recommendations but were treated as hard limits. Patients on stable doses had prescriptions cut abruptly. Some were dismissed by practices unwilling to manage opioid patients. The CDC acknowledged the damage in its 2022 revision, citing untreated pain, withdrawal, psychological distress, and suicidal ideation.

Chronic pain is increasingly understood not as a symptom but as a disease of the nervous system. After months of sustained signaling, nerve pathways become sensitized. The brain’s pain processing centers reorganize. Pain persists not because the original injury is still active but because the nervous system has learned to generate pain on its own. This is why treating the original source, replacing the knee, fusing the disc, sometimes is not enough. The pain has migrated from the joint to the wiring.

Older adults are more vulnerable: inflammatory markers rise with age, sleep disruption interferes with overnight pain modulation, and depression lowers pain thresholds. These form a self-reinforcing cycle.

The first genuinely new pain drug class in two decades, suzetrigine, reached the market in January 2025. It blocks pain signals without acting on the central nervous system, carrying no addiction risk or sedation. It costs $15.50 per pill, roughly $420 per week. Multimodal approaches combining physical therapy, cognitive behavioral therapy, and carefully managed medication remain the strongest evidence-based strategy for older adults with chronic pain. The challenge is access: insurance coverage for physical therapy and psychological pain management is limited, inconsistent, and often inadequate for conditions that require sustained treatment.